213 related articles for article (PubMed ID: 36344941)
1. Exploring the utility and acceptability of Faecal immunochemical testing (FIT) as a novel intervention for the improvement of colorectal Cancer (CRC) surveillance in individuals with lynch syndrome (FIT for lynch study): a single-arm, prospective, multi-centre, non-randomised study.
Lincoln A; Benton S; Piggott C; North BV; Rigney J; Young C; Quirke P; Sasieni P; Monahan KJ
BMC Cancer; 2022 Nov; 22(1):1144. PubMed ID: 36344941
[TBL] [Abstract][Full Text] [Related]
2. Risk-stratified faecal immunochemical testing (FIT) for urgent colonoscopy in Lynch syndrome during the COVID-19 pandemic.
Lincoln AG; Benton SC; Piggott C; Sheikh SR; Beggs AD; Buckley L; DeSouza B; East JE; Sanders P; Lim M; Sheehan D; Snape K; Hanson H; Greenaway JR; Burn J; Nylander D; Hawkins M; Lalloo F; Green K; Lee TJ; Walker J; Matthews G; Rutherford T; Sasieni P; Monahan KJ
BJS Open; 2023 Sep; 7(5):. PubMed ID: 37668669
[TBL] [Abstract][Full Text] [Related]
3. Faecal immunochemical tests versus colonoscopy for post-polypectomy surveillance: an accuracy, acceptability and economic study.
Atkin W; Cross AJ; Kralj-Hans I; MacRae E; Piggott C; Pearson S; Wooldrage K; Brown J; Lucas F; Prendergast A; Marchevsky N; Patel B; Pack K; Howe R; Skrobanski H; Kerrison R; Swart N; Snowball J; Duffy SW; Morris S; von Wagner C; Halloran S
Health Technol Assess; 2019 Jan; 23(1):1-84. PubMed ID: 30618357
[TBL] [Abstract][Full Text] [Related]
4. Faecal haemoglobin can define risk of colorectal neoplasia at surveillance colonoscopy in patients at increased risk of colorectal cancer.
Digby J; Cleary S; Gray L; Datt P; Goudie DR; Steele RJC; Strachan JA; Humphries A; Fraser CG; Mowat C
United European Gastroenterol J; 2020 Jun; 8(5):559-566. PubMed ID: 32213041
[TBL] [Abstract][Full Text] [Related]
5. Faecal immunochemical tests to triage patients with lower abdominal symptoms for suspected colorectal cancer referrals in primary care: a systematic review and cost-effectiveness analysis.
Westwood M; Corro Ramos I; Lang S; Luyendijk M; Zaim R; Stirk L; Al M; Armstrong N; Kleijnen J
Health Technol Assess; 2017 May; 21(33):1-234. PubMed ID: 28643629
[TBL] [Abstract][Full Text] [Related]
6. Population-based colorectal cancer screening programmes using a faecal immunochemical test: should faecal haemoglobin cut-offs differ by age and sex?
Arana-Arri E; Idigoras I; Uranga B; Pérez R; Irurzun A; Gutiérrez-Ibarluzea I; Fraser CG; Portillo I;
BMC Cancer; 2017 Aug; 17(1):577. PubMed ID: 28851318
[TBL] [Abstract][Full Text] [Related]
7. Optimal diagnostic accuracy of quantitative faecal immunochemical test positivity thresholds for colorectal cancer detection in primary health care: A community-based cohort study.
Pin-Vieito N; García Nimo L; Bujanda L; Román Alonso B; Gutierrez-Stampa MÁ; Aguilar-Gama V; Portillo I; Cubiella J
United European Gastroenterol J; 2021 Mar; 9(2):256-267. PubMed ID: 32778002
[TBL] [Abstract][Full Text] [Related]
8. Personalized colorectal cancer screening: study protocol of a mixed-methods study on the effectiveness of tailored intervals based on prior f-Hb concentration in a fit-based colorectal cancer screening program (PERFECT-FIT).
Breekveldt ECH; Toes-Zoutendijk E; de Jonge L; Spaander MCW; Dekker E; van Kemenade FJ; van Vuuren AJ; Ramakers CRB; Nagtegaal ID; van Leerdam ME; Lansdorp-Vogelaar I
BMC Gastroenterol; 2023 Feb; 23(1):45. PubMed ID: 36814185
[TBL] [Abstract][Full Text] [Related]
9. Choice of faecal immunochemical test matters: comparison of OC-Sensor and HM-JACKarc, in the assessment of patients at high risk of colorectal cancer.
Chapman CJ; Banerjea A; Humes DJ; Allen J; Oliver S; Ford A; Hardy K; Djedovic N; Logan RF; Morling JR
Clin Chem Lab Med; 2021 Mar; 59(4):721-728. PubMed ID: 33112776
[TBL] [Abstract][Full Text] [Related]
10. The multitarget fecal immunochemical test versus the fecal immunochemical test for programmatic colorectal cancer screening: a cross-sectional intervention study with paired design.
Wisse PHA; de Klaver W; van Wifferen F; Meiqari L; Bierkens M; Greuter MJE; Carvalho B; van Leerdam ME; Spaander MCW; Dekker E; Coupé VMH; de Wit M; Meijer GA
BMC Cancer; 2022 Dec; 22(1):1299. PubMed ID: 36503495
[TBL] [Abstract][Full Text] [Related]
11. Can quantification of faecal occult blood predetermine the need for colonoscopy in patients at risk for non-syndromic familial colorectal cancer?
Levi Z; Rozen P; Hazazi R; Vilkin A; Waked A; Maoz E; Birkenfeld S; Niv Y
Aliment Pharmacol Ther; 2006 Nov; 24(10):1475-81. PubMed ID: 17032281
[TBL] [Abstract][Full Text] [Related]
12. Cost-effectiveness of the faecal immunochemical test at a range of positivity thresholds compared with the guaiac faecal occult blood test in the NHS Bowel Cancer Screening Programme in England.
Murphy J; Halloran S; Gray A
BMJ Open; 2017 Oct; 7(10):e017186. PubMed ID: 29079605
[TBL] [Abstract][Full Text] [Related]
13. A comparison of the faecal haemoglobin concentrations and diagnostic accuracy in patients suspected with colorectal cancer and serious bowel disease as reported on four different faecal immunochemical test systems.
Benton SC; Piggott C; Zahoor Z; O'Driscoll S; Fraser CG; D'Souza N; Chen M; Georgiou Delisle T; Abulafi M
Clin Chem Lab Med; 2022 Jul; 60(8):1278-1286. PubMed ID: 35637625
[TBL] [Abstract][Full Text] [Related]
14. Systematic review: non-endoscopic surveillance for colorectal neoplasia in individuals with Lynch syndrome.
van Liere ELSA; de Boer NKH; Dekker E; van Leerdam ME; de Meij TGJ; Ramsoekh D
Aliment Pharmacol Ther; 2022 Apr; 55(7):778-788. PubMed ID: 35181895
[TBL] [Abstract][Full Text] [Related]
15. The proportion of endometrial tumours associated with Lynch syndrome (PETALS): A prospective cross-sectional study.
Ryan NAJ; McMahon R; Tobi S; Snowsill T; Esquibel S; Wallace AJ; Bunstone S; Bowers N; Mosneag IE; Kitson SJ; O'Flynn H; Ramchander NC; Sivalingam VN; Frayling IM; Bolton J; McVey RJ; Evans DG; Crosbie EJ
PLoS Med; 2020 Sep; 17(9):e1003263. PubMed ID: 32941469
[TBL] [Abstract][Full Text] [Related]
16. Diagnostic accuracy of a quantitative faecal immunochemical test vs. symptoms suspected for colorectal cancer in patients referred for colonoscopy.
Tsapournas G; Hellström PM; Cao Y; Olsson LI
Scand J Gastroenterol; 2020 Feb; 55(2):184-192. PubMed ID: 31906738
[No Abstract] [Full Text] [Related]
17. Multiple rounds of one sample versus two sample faecal immunochemical test-based colorectal cancer screening: a population-based study.
Schreuders EH; Grobbee EJ; Nieuwenburg SAV; Kapidzic A; van Roon AHC; van Vuuren AJ; Lansdorp-Vogelaar I; Spijker WWJ; Izelaar K; Bruno MJ; Kuipers EJ; Spaander MCW
Lancet Gastroenterol Hepatol; 2019 Aug; 4(8):622-631. PubMed ID: 31196734
[TBL] [Abstract][Full Text] [Related]
18. Detection of advanced colorectal neoplasia and relative colonoscopy workloads using quantitative faecal immunochemical tests: an observational study exploring the effects of simultaneous adjustment of both sample number and test positivity threshold.
Young GP; Woodman RJ; Symonds E
BMJ Open Gastroenterol; 2020 Sep; 7(1):. PubMed ID: 32994195
[TBL] [Abstract][Full Text] [Related]
19. The "unnatural" history of colorectal cancer in Lynch syndrome: Lessons from colonoscopy surveillance.
Ahadova A; Seppälä TT; Engel C; Gallon R; Burn J; Holinski-Feder E; Steinke-Lange V; Möslein G; Nielsen M; Ten Broeke SW; Laghi L; Dominguez-Valentin M; Capella G; Macrae F; Scott R; Hüneburg R; Nattermann J; Hoffmeister M; Brenner H; Bläker H; von Knebel Doeberitz M; Sampson JR; Vasen H; Mecklin JP; Møller P; Kloor M
Int J Cancer; 2021 Feb; 148(4):800-811. PubMed ID: 32683684
[TBL] [Abstract][Full Text] [Related]
20. Faecal immunochemical test after negative colonoscopy may reduce the risk of incident colorectal cancer in a population-based screening programme.
Peng SM; Hsu WF; Wang YW; Lin LJ; Yen AM; Chen LS; Lee YC; Wu MS; Chen TH; Chiu HM
Gut; 2021 Jul; 70(7):1318-1324. PubMed ID: 32989019
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
